Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
A Position Statement on Endovascular Models and Effectiveness Metrics for Mechanical Thrombectomy Navigation, on behalf of the Stakeholder Taskforce for AI-assisted Robotic Thrombectomy (START)
0
Zitationen
23
Autoren
2026
Jahr
Abstract
While we are making progress in overcoming infectious diseases and cancer; one of the major medical challenges of the mid-21st century will be the rising prevalence of stroke. Large vessels occlusions are especially debilitating, yet effective treatment (needed within hours to achieve best outcomes) remains limited due to geography. One solution for improving timely access to mechanical thrombectomy in geographically diverse populations is the deployment of robotic surgical systems. Artificial intelligence (AI) assistance may enable the upskilling of operators in this emerging therapeutic delivery approach. Our aim was to establish consensus frameworks for developing and validating AI-assisted robots for thrombectomy. Objectives included standardizing effectiveness metrics and defining reference testbeds across in silico, in vitro, ex vivo, and in vivo environments. To achieve this, we convened experts in neurointervention, robotics, data science, health economics, policy, statistics, and patient advocacy. Consensus was built through an incubator day, a Delphi process, and a final Position Statement. We identified that the four essential testbed environments each had distinct validation roles. Realism requirements vary: simpler testbeds should include realistic vessel anatomy compatible with guidewire and catheter use, while standard testbeds should incorporate deformable vessels. More advanced testbeds should include blood flow, pulsatility, and disease features. There are two macro-classes of effectiveness metrics: one for in silico, in vitro, and ex vivo stages focusing on technical navigation, and another for in vivo stages, focused on clinical outcomes. Patient safety is central to this technology's development. One requisite patient safety task needed now is to correlate in vitro measurements to in vivo complications.
Ähnliche Arbeiten
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.
1993 · 12.148 Zit.
Correspondence - Tranexamic acid for traumatic brain injury
2005 · 11.712 Zit.
Tissue Plasminogen Activator for Acute Ischemic Stroke
1995 · 11.632 Zit.
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 · 11.554 Zit.
Beneficial Effect of Carotid Endarterectomy in Symptomatic Patients with High-Grade Carotid Stenosis
1991 · 8.418 Zit.
Autoren
- Harry Robertshaw
- Anna Barnes
- Phil Blakelock
- Raphael Blanc
- Robert Crossley
- Rebecca Fahrig
- Ameer E. Hassan
- Benjamin Jackson
- Lennart Karstensen
- Neelam Kaur
- Markus Kowarschik
- Jeremy Lynch
- Franziska Mathis-Ullrich
- Dwight Meglan
- Vitor Mendes Pereira
- Mouloud Ourak
- Matteo Pantano
- S. M. Hadi Sadati
- Alice Taylor-Gee
- Tom Vercauteren
- P White
- Alejandro Granados
- Thomas C. Booth